Acorn Capital Advisors has reduced its stake in Terns Pharmaceuticals by selling 225,000 shares, valued at approximately $5.20 million, as revealed in a recent SEC filing. Despite this sale, Terns remains Acorn’s largest holding, constituting about 24% of its 13F assets under management, reflecting continued confidence in the biotech firm’s potential.

Terns Pharmaceuticals has seen its stock price surge by 1,400% over the past year, significantly outpacing the S&P 500’s 15% gain. The company focuses on developing therapies for non-alcoholic steatohepatitis (NASH) and obesity, with a robust pipeline and approximately $1 billion in cash, which positions it well for future trials and operational flexibility. Recent operational pivots towards oncology have also shown promising results.

For market professionals, this transaction underscores a strategic repositioning rather than a lack of confidence, highlighting Terns’ strong market performance and the potential for continued growth in the biotech sector.

Source: fool.com